Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects

• Published in: Antimicrobial Agents and Chemotherapy Vol. 62; no. 5
• Main Authors: Vandell, Alexander G., Inoue, Satoshi, Dennie, Justin, Nagasawa, Yasuo, Gajee, Roohi, Pav, Joe, Zhang, George, Zamora, Cynthia, Masuda, Nobuhisa, Senaldi, Giorgio
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.05.2018
• Subjects: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Bacteroides fragilis; Bifidobacterium; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Drug Administration Schedule; Experimental Therapeutics; Female; Gastrointestinal Microbiome; Healthy Volunteers; Humans; Male; Middle Aged; Prevotella; Topoisomerase II Inhibitors; Young Adult; DS-2969b; antibiotic; infection; antimicrobial agents; Clostridium difficile
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/aac.02537-17

DS-2969b is a novel GyrB inhibitor in development for the treatment of Clostridium difficile infection (CDI). The aim of this study was to assess the safety, tolerability, pharmacokinetics, and effects on the normal gastrointestinal microbiota of multiple daily oral ascending doses of DS-2969b in healthy subjects. The study enrolled three sequential ascending-dose cohorts (60 mg, 200 mg, and 400 mg). In each cohort, subjects received an oral dose of DS-2969b or placebo (six subjects received DS-2969b, and two received placebo) each morning for 14 days. DS-2969b was safe and well tolerated at all dose levels examined. All adverse events related to DS-2969b were mild and predominantly related to the gastrointestinal tract. DS-2969a (free form of DS-2969b) plasma concentrations increased with increasing doses; however, both the maximum concentration of drug in serum ( C max ) and the area under the concentration-time curve (AUC) increased less than dose proportionally. In all cohorts, sufficient fecal levels of DS-2969a were achieved within 24 h following the administration of the first dose and maintained for at least 17 days. Following treatment with DS-2969b, clear reductions in the populations of Clostridium coccoides and Bifidobacterium groups were observed. However, populations of three other bacterial groups examined ( Bacteroides fragilis , Clostridium leptum , and Prevotella ) were not affected. Data from this study support and encourage the further development of DS-2969b as a novel treatment for CDI.